Fernando Camacho
Aventis Pharma
13 Papers
63 Citations
Fernando Camacho is an academic researcher from Aventis Pharma. The author has contributed to research in topics: Acetylcholinesterase inhibitor & Period Circadian Proteins. The author has an hindex of 7, co-authored 13 publications.
Chat about Author
Papers
Control of Mammalian Circadian Rhythm by CKIε-Regulated Proteasome-Mediated PER2 Degradation
Erik J. Eide,Margaret F. Woolf,Heeseog Kang,Peter J. Woolf,William J Hurst,Fernando Camacho,Erica L. Vielhaber,Andrew Giovanni,David M. Virshup,David M. Virshup +9 more
TL;DR: A cell-based model of PER2 degradation provides a biochemical mechanism and functional relevance for the observed phosphorylation-degradation cycle of mammalian PER2, and supports the idea that CKIε inhibition causes a significant lengthening of circadian period in synchronized Rat-1 cells.
491
•Journal Article
Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine.
Gina M. Bores,F P Huger,Wayne W. Petko,A E Mutlib,Fernando Camacho,Douglas K. Rush,David E. Selk,V Wolf,R W Kosley,Larry Davis,Hugo M. Vargas +10 more
TL;DR: Because of its composite profile, including duration of action, oral therapeutic index and pharmacokinetics, P11149 is considered the better therapeutic candidate for the treatment of Alzheimer's disease.
268
•Journal Article
Pharmacological Activity and Safety Profile of P10358, a Novel, Orally Active Acetylcholinesterase Inhibitor for Alzheimer’s Disease
Craig P. Smith,Gina M. Bores,Wayne W. Petko,Mary Li,David E. Selk,Douglas K. Rush,Fernando Camacho,James T. Winslow,Rod J. Fishkin,D. Cunningham,Karen M. Brooks,Joachim E. Roehr,Harold B. Hartman,Larry Davis,Hugo M. Vargas +14 more
TL;DR: P10358 had weak affinity at a variety of aminergic and peptidergic receptors and uptake carriers and suggest that P10358 may be a safe and promising symptomatic treatment for Alzheimer's disease.
37
Patent
Substituted 1h-pyrrolo[3,2-b, 3,2-c, and 2,3-c]pyridine-2-carboxamides and related analogs as inhibitors of casein kinase i epsilon
Metz William Arthur,Frank Halley,Gilles Dutruc-Rosset,Yong Mi Choi-Sledeski,Poli Gregory B,Fink David M,Gilles Doerflinger,Bao-Guo Huang,Ann Marie Gelormini,Juan A Gamboa,Andrew Giovanni,Joachim E. Roehr,Joseph T. Tsay,Fernando Camacho,William J Hurst,Stephen W Harnish,Yulin Chiang +16 more
- 01 Dec 2004
TL;DR: In this paper, the present invention discloses and claims substituted 1H-pyrrolo[3,2-b]pyridine-2-carboxamides, 1H pyrroloencocaine[2,3]-pyrrole[1,2]-polycyclic acid[1.5] pyrrole [1.7] and 1Hpyrrocyclo[2.3]-polyclamide [2.2]-pythane[2] for inhibitors of human casein kinase I Epsilon.
24
Synthesis and preliminary structure-activity relationships of 1-[(3-fluoro-4-pyridinyl)amino]-3-methyl-1H-indol-5-yl methyl carbamate (P10358), a novel acetylcholinesterase inhibitor
Lawrence L. Martin,Larry Davis,Klein Joseph Thomas,Peter Allen Nemoto,Olsen Gordon Edward,Gina M. Bores,Fernando Camacho,Wayne W. Petko,Douglas K. Rush,David E. Selk,Craig P. Smith,Hugo M. Vargas,James T. Winslow,Richard C. Effland,Fink David M +14 more
TL;DR: A series of carbamate analogs of besipirdine (HP 749) was synthesized as potential agents with enhanced cholinomimetic properties for the treatment of Alzheimer's disease Compound 5a (P10358, 1-[3-fluoro-4-pyridinyl]amino]-3-methyl-1H-indol-5-yl methyl carbamate) emerged as a potent, reversible acetylcholinesterase inhibitor that significantly enhanced performance on oral or parenteral administration in learning and memory paradigms as discussed by the authors.
21